GiveBetter x California

National Health Law Program

Health-access litigation, policy advocacy and legal-aid support

Research time: ~26 min on GPT-6 Astra Light
  • Research — reviewed programs, finances and impact evidence.

Updated: 2026-09-13

Donate

Summary

What do they do? NHeLP uses litigation, policy analysis and legal-aid support to protect access to health care. Its California team works on Medi-Cal and consumer access, while national implementation cases can also benefit Californians. Our weak-confidence estimate is about $35.5 million per 10 California QALYs for a Medicaid-rule pathway, with other portfolio health unquantified.

Why we’re interested in this organization:

  • A direct rights-to-effective-care mechanism can affect many people at once.

  • Current original audits distinguish recipient costs, restricted funding and donated legal labor.

  • California expertise connects policy work to local health-access problems.

Our main reservations:

  • Court filings and policy participation do not identify marginal donation credit.

  • California's share of this policy pathway is modeled; its share of all recipient benefit remains unknown.

  • Substantial existing funding and reserves complicate claims that a new gift buys an extra lawyer or changes a case outcome.

What do you get for your dollar? $35.5M per better life: ten additional quality-adjusted life years in California. Medicaid-rule health only; policy effect modeled.

Additional Medicaid enrollment, then genuinely additional insured person-years with effective access; finite QALY utility differences. Filings, fiscal transfers and legal wins are not health units.

1. What do they do?

This report covers the entire charitable recipient, National Health Law Program, EIN 95-3080947, rather than only its California office. The dedicated California program combines policy advocacy, litigation and a Health Consumer Alliance support-center role. National federal work can also affect California residents. California advocacy and support-center role Strategic framework 2023–2027

The current docket includes lead or co-counsel cases and amicus participation; those are different causal roles. September 2026 appellate briefs, Medicaid disputes in other states and California-related federal challenges demonstrate an active mixed geographic portfolio, not an aggregate California benefit estimate. Current litigation portfolio

2. Monitoring and information sharing

The health endpoint is effective care obtained or delay avoided, not a lawsuit filed, insured person named in a rule, or bill canceled. Health Consumer Alliance accounts include both restored access and debt disputes after treatment; those cannot all be valued as newly delivered care. Local legal-aid representation must be separated from NHeLP's support-center contribution. Health Consumer Alliance services and client accounts

Oregon's randomized Medicaid evidence supports increased utilization and improved self-reported health/depression, but did not show significant measured physical-health or mortality effects over the initial follow-up. A later economic analysis maps self-rated health to QALYs; its population and coverage contrast are not a direct estimate for legal-policy work in California. The Value of Medicaid: Interpreting Results from the Oregon Health Insurance Experiment

Request a case-level chain from incremental funded capacity to changed policy implementation, distinct affected people, effective uptake, finite duration and health outcomes, including unsuccessful and displaced work.

The forecast describes enrollment at a point within each year, not integrated insured person-years. Our central calculation assumes that difference persists for a full benefit year; a half-year average reduces modeled health by half. Replacement coverage and the scope a legal remedy could actually change are discounted separately.

3. Qualitative assessment

A concrete current pathway is enforcing timely behavioral-health access. NHeLP's June 2026 review identifies repeated commercial-plan failures and calls for follow-up and implementation accountability. These investigations concern a specified commercial-plan domain, not all Medi-Cal beneficiaries. California commercial-plan behavioral-health investigation analysis

The original regulator schedule shows a publicly financed investigation program underway across multiple phases, with additional 2026 reviews and some reviews postponed because other enforcement or plan changes were already in progress. A donation therefore cannot receive credit for the entire regulatory program; its plausible contribution is improving implementation or timing beyond that baseline. Behavioral health investigation phases and plan changes

Policy health benefits may be substantial, but a small direct-assistance proxy would omit the recipient's primary strategic value. Fiscal transfers and rights protection also have value outside QALYs; this report does not silently monetize them as health.

4. What do you get for your dollar?

A weak-confidence estimate for the Medicaid-rule implementation pathway is about $35.5 million per 10 California QALYs. It retains three years of the entire recipient's latest audited cost, $39,107,481, while modeling about 11.0 California QALYs over two benefit years. This is a policy-pathway estimate with other portfolio net health provisionally zero, not a measured whole-portfolio return or proven lower bound.

The national model starts from Manatt's 1.9 million annual difference between statutory-language and CMS-rule enrollment forecasts for2028–29. It applies .5 for realized/remediable scope, .5 for genuinely avoiding uninsurance, .02 QALYs per insured year, .1 incremental coalition influence, .1 NHeLP attribution and .25 financial additionality. Those are explicit subjective judgments; the current amicus role identifies neither a ten-percent causal share nor an unfunded staffing elasticity. Benefits are discounted3% in years2 and3 and then stop.

For California, the original state table gives a 2028 forecast difference of474,000 (2,147,000 minus1,673,000), versus1,900,000 nationally. Applying g=474/1900 to the shared national model gives11.007095 California QALYs. Carrying the2028share into2029 and assuming comparable conditional remedy, insurance replacement and health yield are transfer judgments. This is not California's share of all NHeLP work. Original Manatt state forecast

The brief addresses medically-frail exemptions and self-attestation, narrower than eliminating the federal law. Current legal work and public administrators remain in the counterfactual. Zero policy change, zero health benefit or complete financing substitution removes the modeled benefit; adverse public-resource or other-portfolio effects may make net health negative. Public treatment expenditures are outside the recipient numerator, so this is not full social cost-effectiveness. Original September10 amicus

Model, assumptions and sensitivity

Three years of all recipient programs/support at FY2025 audited resource cost including donated legal labor. One national implementation pathway quantified; other portfolio net health set zero, not a proven lower bound. Public treatment and wider social costs excluded.

Specific Medicaid-rule pathway only, not whole-recipient share. Manatt Table2's 2028 CA difference=(2147−1673)*1000=474000; national=(8606−6706)*1000=1900000. g=474/1900=.2494736842. Applying this share to 2029 and other scenario years, and assuming equal conditional remedy, replacement coverage, utility and advocacy yield across states, are explicit judgments. Table1's 2027–34 average451/1808=.2494469 is a consistency check, not the chosen temporal denominator.

A=sum(t=start..start+T-1)(1+discount)^(-t); V=N*r*u*A; H=V*q; Q_all=b*(p*a*H-h); Q_CA=g*Q_all; Cost=C*Y; Price10=10*Cost/Q_CA when positive. Central g=(2147-1673)/(8606-6706)=474/1900. National enrollment snapshots are assumed sustained over each credited year; q is a sustained annual utility judgment. All-population outcomes match the national view; California and USA are not additive donations.

C
13035827 USD annual recipient resources (observed). Full audited expense, all functions and recognized donated professional services; original review reused from CA worker. [audit25]
Y
3 funding years (judgment). Three-year capacity cohort, not a priced brief; constant latest expense.
N
1900000 annual Medicaid enrollment difference (observed). Published forecast, not realized outcome: Figure 1 2028 8.6m−6.7m and 2029 8.8m−6.9m; visually verified rounded values. Point-in-year forecast treated as sustained for a full year; this is a temporal approximation, not an observed person-year integral. [nhelp-manatt]
r
0.5 realized/remediable share of forecast (judgment). Half allows forecast error, narrower remedy and incomplete state implementation. [nhelp-manatt] [nhelp-amicus]
u
0.5 share genuinely preventing uninsurance (judgment). Half allows other public/private insurance and enrollment-accounting differences. Effective health among newly insured is separately q. [oregon]
q
0.02 QALYs per additional insured year (judgment). .02 transfer below Oregon's .05 self-rated mapping. No separate mortality, depression or financial benefit added. Assumes the utility improvement persists throughout each credited insured year. [oregon]
p
0.1 incremental coalition probability/intensity improvement (judgment). Ten percentage points from further coalition work over three years beyond baseline public action; not overall litigation success probability. [nhelp-prepare] [nhelp-cms]
a
0.1 NHeLP share of coalition effect (judgment). Ten percent recognizes co-authorship and national expertise; 90% remains with states, other counsel and organizations. Not 1/71 arithmetic or filing credit. [nhelp-amicus] [cases]
b
0.25 marginal capacity additionality (judgment). Quarter allows grants, reserves and other donors; local linearity could fail and zero is possible. [audit25] [careers]
start
2 first benefit year (judgment). Year two approximately 2028, allowing preparation lag; no first-year credit.
T
2 benefit years (judgment). Two years approximately 2028–29 then paths reconverge; no perpetual entitlement credit.
discount
0.03 annual discount fraction (judgment). 3% applied by health event year; no remaining-life multiplication.
h
0 other net health harm before b (judgment). Net zero for unpriced portfolio and public-resource displacement, not established zero; adverse sensitivities independent of p*a.
CA2028 rule-related enrollment difference
474000 forecast Medicaid enrollees (observed). Published rounded Table2 forecasts2147k−1673k, visually checked; not realized enrollment. [nhelp-manatt]
g
0.24947368421052632 California share of pathway health (judgment). 2028 forecast share474k/1900k applied to2029 and conditional health/influence yields; not an observed health share or organization geography. [nhelp-manatt]

Weak-confidence California rule-implementation estimate: Cost: $39.1M; California QALYs: 11.007095093284967; all-population QALYs: 44.12126725156421. {"C":13035827,"Y":3,"N":1900000,"r":0.5,"u":0.5,"q":0.02,"p":0.1,"a":0.1,"b":0.25,"start":2,"T":2,"discount":0.03,"g":0.24947368421052632,"h":0}; A=1.857737568486914; conditional discounted insured person-years=882425.3450312841; conditional QALYs=17648.50690062568.; California g=474/1900, temporal and relative-health-yield transfer judgment.

Broader sustained effect: Cost: $39.1M; California QALYs: 1847.433994530761; all-population QALYs: 7405.326138414443. {"C":13035827,"Y":3,"N":1900000,"r":1,"u":0.8,"q":0.05,"p":0.3,"a":0.15,"b":0.6,"start":2,"T":4,"discount":0.03,"g":0.24947368421052632,"h":0}; A=3.608833400786766; conditional discounted insured person-years=5485426.7691958845; conditional QALYs=274271.33845979423.; California g=474/1900, temporal and relative-health-yield transfer judgment.

Very weak influence and access: Cost: $39.1M; California QALYs: 0.0004467904609293996; all-population QALYs: 0.0017909322273541334. {"C":13035827,"Y":3,"N":1900000,"r":0.1,"u":0.2,"q":0.005,"p":0.02,"a":0.01,"b":0.05,"start":2,"T":1,"discount":0.03,"g":0.24947368421052632,"h":0}; A=0.9425959091337544; conditional discounted insured person-years=35818.644547082666; conditional QALYs=179.09322273541332.; California g=474/1900, temporal and relative-health-yield transfer judgment.

Use .05 health mapping: Cost: $39.1M; California QALYs: 27.517737733212424; all-population QALYs: 110.30316812891056. {"C":13035827,"Y":3,"N":1900000,"r":0.5,"u":0.5,"q":0.05,"p":0.1,"a":0.1,"b":0.25,"start":2,"T":2,"discount":0.03,"g":0.24947368421052632,"h":0}; A=1.857737568486914; conditional discounted insured person-years=882425.3450312841; conditional QALYs=44121.26725156421.; California g=474/1900, temporal and relative-health-yield transfer judgment.

Only 5% additional capacity: Cost: $39.1M; California QALYs: 2.2014190186569937; all-population QALYs: 8.824253450312844. {"C":13035827,"Y":3,"N":1900000,"r":0.5,"u":0.5,"q":0.02,"p":0.1,"a":0.1,"b":0.05,"start":2,"T":2,"discount":0.03,"g":0.24947368421052632,"h":0}; A=1.857737568486914; conditional discounted insured person-years=882425.3450312841; conditional QALYs=17648.50690062568.; California g=474/1900, temporal and relative-health-yield transfer judgment.

No implementation change: Cost: $39.1M; California QALYs: 0; all-population QALYs: 0. {"C":13035827,"Y":3,"N":1900000,"r":0.5,"u":0.5,"q":0.02,"p":0,"a":0.1,"b":0.25,"start":2,"T":2,"discount":0.03,"g":0.24947368421052632,"h":0}; A=1.857737568486914; conditional discounted insured person-years=882425.3450312841; conditional QALYs=17648.50690062568.; California g=474/1900, temporal and relative-health-yield transfer judgment.

No additional health from coverage: Cost: $39.1M; California QALYs: 0; all-population QALYs: 0. {"C":13035827,"Y":3,"N":1900000,"r":0.5,"u":0.5,"q":0,"p":0.1,"a":0.1,"b":0.25,"start":2,"T":2,"discount":0.03,"g":0.24947368421052632,"h":0}; A=1.857737568486914; conditional discounted insured person-years=882425.3450312841; conditional QALYs=0.; California g=474/1900, temporal and relative-health-yield transfer judgment.

Only substitute existing financing: Cost: $39.1M; California QALYs: 0; all-population QALYs: 0. {"C":13035827,"Y":3,"N":1900000,"r":0.5,"u":0.5,"q":0.02,"p":0.1,"a":0.1,"b":0,"start":2,"T":2,"discount":0.03,"g":0.24947368421052632,"h":0}; A=1.857737568486914; conditional discounted insured person-years=882425.3450312841; conditional QALYs=17648.50690062568.; California g=474/1900, temporal and relative-health-yield transfer judgment.

No policy benefit plus 50 QALYs harm: Cost: $39.1M; California QALYs: -3.118421052631579; all-population QALYs: -12.5. {"C":13035827,"Y":3,"N":1900000,"r":0.5,"u":0.5,"q":0.02,"p":0,"a":0.1,"b":0.25,"start":2,"T":2,"discount":0.03,"g":0.24947368421052632,"h":50}; A=1.857737568486914; conditional discounted insured person-years=882425.3450312841; conditional QALYs=17648.50690062568.; California g=474/1900, temporal and relative-health-yield transfer judgment.

200 QALYs other net harm: Cost: $39.1M; California QALYs: -1.466589117241349; all-population QALYs: -5.878732748435787. {"C":13035827,"Y":3,"N":1900000,"r":0.5,"u":0.5,"q":0.02,"p":0.1,"a":0.1,"b":0.25,"start":2,"T":2,"discount":0.03,"g":0.24947368421052632,"h":200}; A=1.857737568486914; conditional discounted insured person-years=882425.3450312841; conditional QALYs=17648.50690062568.; California g=474/1900, temporal and relative-health-yield transfer judgment.

Twofold future cost: Cost: $78.2M; California QALYs: 11.007095093284967; all-population QALYs: 44.12126725156421. {"C":26071654,"Y":3,"N":1900000,"r":0.5,"u":0.5,"q":0.02,"p":0.1,"a":0.1,"b":0.25,"start":2,"T":2,"discount":0.03,"g":0.24947368421052632,"h":0}; A=1.857737568486914; conditional discounted insured person-years=882425.3450312841; conditional QALYs=17648.50690062568.; California g=474/1900, temporal and relative-health-yield transfer judgment.

Lower California relative implementation/health exposure: Cost: $39.1M; California QALYs: 4.412126725156422; all-population QALYs: 44.12126725156421. g=.1 subjective stress case; national model unchanged.

Higher California relative implementation/health exposure: Cost: $39.1M; California QALYs: 17.648506900625687; all-population QALYs: 44.12126725156421. g=.4 subjective stress case; national model unchanged.

Counterfactual: Existing state litigation, other amici, public administrators, grants and clinical care continue. Only further work's change in strict versus less restrictive administration counts, not repeal or all losses. r removes forecast/remedy overreach, u removes replacement coverage, b removes financial substitution.

Attribution: p=.1 incremental coalition contribution, a=.1 NHeLP share and b=.25 funding additionality are separate subjective factors. Current amicus and strategy show a live role but identify none of them. Existing work receives no automatic future-donation credit.

Weak-confidence, explicitly subjective policy-pathway best estimate. Finite central is useful conditional on the shared USA judgments; it is not a measured portfolio return or rigorous lower bound. Clinical, policy and financial priors dominate the source-observed geographic ratio. Root may reject numerical acceptance. Other California and national portfolio health is set net zero, not proven absent.

Sensitivity

  • Central California Q=11.007095093284967; price10=35529338.729759924. This is the national implementation scenario's CA share, with entire recipient three-year cost retained.
  • At the same national health total, g=.1 yields price10=88636350.30476949 and g=.4 yields 22159087.57619237. These are stress tests, not confidence bounds.
  • A 2028-only California benefit omits2029 entirely and roughly doubles the price; permanent credit is not allowed.
  • Shared national policy influence p=.1, NHeLP attribution a=.1 and financing b=.25 are judgments; changing the geographic denominator does not validate them.
  • If California-specific other net harm exceeds44.02838 QALYs before financial additionality, it erases the central CA gain. The source does not measure public resource displacement or other portfolio health.
  • If the point-in-year enrollment difference persists for only half of each modeled benefit year, health is halved and cost per 10 QALYs doubles. This temporal assumption is distinct from replacement coverage.

Unresolved inputs

  • Costed unfunded implementation plan and staffing/output response given current grants and reserves.
  • Case/administrative outcomes with and without incremental NHeLP capacity, separate from states and other counsel.
  • Actual state implementation, remedy scope, duration, uptake and alternative coverage.
  • Current beneficiary utility, public treatment/opportunity costs and other portfolio health/harms.
  • State-year California forecast and remediable medically-frail subgroup, actual California implementation, alternate coverage and utility; current share is an explicit transfer assumption.

5. Funding and previous grants

Audited calendar-year expenses are $11,023,768 in 2023, $11,725,264 in 2024 and $13,035,827 in 2025: a comparable mean of $11,928,286.33. 2024 audited financial statements with 2023 comparative 2025 audited financial statements

The 2025 audit records $20,349,524 revenue and $33,596,890 ending net assets, including $21,527,078 without donor restrictions and $12,069,812 restricted. Its $339,667 donated professional services are noncash legal labor, not additional cash treatment spending. Large grant concentration and restrictions matter; the surplus does not establish either unlimited capacity or a particular unfunded opportunity. The audit opinion is dated March 27, 2026; that is not asserted as its publication date. 2025 audited financial statements

The careers page shows no specific current opening in its displayed opportunities section. This is not proof of no staffing need, but historical advertisements cannot establish a present cash bottleneck. An ordinary donation route is verified; no restricted California allocation or recipient commitment was assumed. Current job opportunities Official donation route

Annual expenses

Organization-level spending, including programs, administration and fundraising. The research list averages three comparable, consecutive full fiscal years when available.

  • FY 2023: $11.0M; National Health Law Program, Inc., 12-month period, GAAP accrual audited. Source
  • FY 2024: $11.7M; National Health Law Program, Inc., 12-month period, GAAP accrual audited. Source
  • FY 2025: $13.0M; National Health Law Program, Inc., 12-month period, GAAP accrual audited. Source

6. Sources

  1. 2025 audited financial statements. National Health Law Program. Published: not stated; retrieved: 2026-09-13.
  2. 2024 audited financial statements with 2023 comparative. National Health Law Program. Published: not stated; retrieved: 2026-09-13.
  3. Current original financial-document index. National Health Law Program. Published: not stated; retrieved: 2026-09-13.
  4. California advocacy and support-center role. National Health Law Program. Published: not stated; retrieved: 2026-09-13.
  5. Strategic framework 2023–2027. National Health Law Program. Published: not stated; retrieved: 2026-09-13.
  6. Current litigation portfolio. National Health Law Program. Published: not stated; retrieved: 2026-09-13.
  7. California commercial-plan behavioral-health investigation analysis. National Health Law Program. Published: 2026-06-18; retrieved: 2026-09-13.
  8. Behavioral health investigation phases and plan changes. California Department of Managed Health Care. Published: not stated; retrieved: 2026-09-13.
  9. Health Consumer Alliance services and client accounts. Health Consumer Alliance. Published: not stated; retrieved: 2026-09-13.
  10. The Value of Medicaid: Interpreting Results from the Oregon Health Insurance Experiment. Finkelstein, Hendren and Luttmer, Journal of Political Economy. Published: not stated; retrieved: 2026-09-13.
  11. Current job opportunities. National Health Law Program. Published: not stated; retrieved: 2026-09-13.
  12. Official donation route. National Health Law Program. Published: not stated; retrieved: 2026-09-13.
  13. National Medicaid implementation strategy. National Health Law Program. Published: not stated; retrieved: 2026-09-14.
  14. Medically-frail exemption amicus. NHeLP and co-amici. Published: 2026-09-10; retrieved: 2026-09-14.
  15. Work requirement IFR comments. National Health Law Program. Published: 2026-07-31; retrieved: 2026-09-14.
  16. Nationwide Medicaid work requirement framework. CMS. Published: 2026-06-01; retrieved: 2026-09-14.
  17. 50-state additional coverage-loss model, Figure 1 and methodology. Manatt Health / Boozang and colleagues. Published: 2026-07-16; retrieved: 2026-09-14.